Qiagen N.V.

Equities

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 17/05/2024 BST			5-day change	1st Jan Change
45.69 ^USD	-0.65%		+4.77%	+2.05%

05-15	Qiagen's Updated Clinical Decision Support Platform Secures EU Certification	MT
05-14	QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret	CI

Qiagen N : QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance

April 30, 2024 at 08:09 am

Qiagen N.V.

Qiagen N.V.

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date29 apr 2024 - 21:55

Statutory nameQiagen N.V.

TitleQIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance

Previous result

Next result

Related downloads

202404290000000017_2024-04-29 Press release QIAGEN_Q1 2024 results_EN_FINAL.pdf(opens in a new window)

Date last update: 30 April 2024

Attachments

Original Link
Permalink

Disclaimer

Qiagen NV published this content on 29 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 April 2024 07:08:26 UTC.

Latest news about Qiagen N.V.

Qiagen's Updated Clinical Decision Support Platform Secures EU Certification	05-15	MT
QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret	05-14	CI
Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test	05-13	MT
Qiagen Obtains US FDA Clearance for Respiratory Syndromic Testing Panel	05-13	MT
Qiagen, US FBI to Jointly Develop Digital PCR Assay for Forensics	05-08	MT
QIAGEN Partners with FBI to Develop Digital PCR Assay for QIAcuity for Use in Forensics	05-07	CI
QIAGEN Announces the Availability of QCI Secondary Analysis	05-02	CI
QIAGEN NV : Berenberg reaffirms its Buy rating	04-30	ZD
QIAGEN : A decent start to 2024; guidance unchanged	04-30
QIAGEN NV : Deutsche Bank reiterates its Buy rating	04-30	ZD
Qiagen Seeks Acquisitions	04-30	CI
Transcript : Qiagen N.V., Q1 2024 Earnings Call, Apr 30, 2024	04-30
QIAGEN NV : Jefferies remains Neutral	04-30	ZD
QIAGEN NV : UBS remains Neutral	04-30	ZD
QIAGEN NV : UBS remains Neutral	04-30	ZD
QIAGEN NV : UBS sticks Neutral	04-30	ZD
Qiagen Q1 Adjusted Earnings, Sales Decline; Q2 Outlook Issued, 2024 Guidance Affirms -- Shares Fall After Hours	04-29	MT
Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024	04-29	CI
Qiagen N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-28	CI
QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use	04-24	CI
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	04-22	MT
QIAGEN NV : Deutsche Bank reiterates its Buy rating	04-16	ZD
Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024	04-03	CI
Mybio Are the New Exclusive Partner for Qiagen in Ireland & Northern Ireland	03-27	CI
QIAGEN Introduces QIAstat-Dx Analyzer 2.0 with Remote Test Results Access, Enhancing Collaboration Across Healthcare System	03-25	CI

Chart Qiagen N.V.

Duration

Period

More charts

Company Profile

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Sector

Biotechnology & Medical Research

Calendar

22/05/2024 - Deutsche Bank dbAccess European Champions Conference

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 02:32 pm

More Strategies

Ratings for Qiagen N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

45.69 USD

Average target price

50.19 USD

Spread / Average Target

+9.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QIAGEN N.V.	+2.05%	10.14B
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research